William D. Tap, MD

Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Paper 21 - PHASE 1 RESULTS OF THE WEE1 INHIBITOR, AZENOSERTIB, IN COMBINATION WITH GEMCITABINE IN ADULT AND PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST

• CME/CE Symposium: A Joint Effort to Improve Care in Tenosynovial Giant Cell Tumors: Applying a Collaborative Approach When Integrating Targeted Therapies in Practice

  Thursday, November 14, 2024
  6:30 PM – 8:15 PM PST

• Paper 45 - A PHASE II STUDY OF PALBOCICLIB COMBINED WITH THE PD-1 INHIBITOR RETIFANLIMAB IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 79 - PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN LOCALLY ADVANCED OR METASTATIC IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA UNTREATED OR PREVIOUSLY TREATED WITH 1 SYSTEMIC TREATMENT REGIMEN (CHONQUER)

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST

• Paper 89 - PERIPHERAL BLOOD T CELL PHENOTYPE AND TUMOR MICROENVIRONMENT SUBTYPE ARE INDEPENDENTLY ASSOCIATED WITH IMMUNE CHECKPOINT BLOCKADE OUTCOMES IN SARCOMAS

  Saturday, November 16, 2024
  10:30 AM – 12:00 PM PST

• Paper 100 - REDEFINING RADIOLOGIC RESPONSE IN EPITHELIOID HEMANGIOENDOTHELIOMA: BEYOND RECIST?

  Saturday, November 16, 2024
  2:00 PM – 3:00 PM PST

• Paper 105 - EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST

• Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST

• Paper 107 - PEXIDARTINIB USE IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: AN ANALYSIS OF THE PHASE III RANDOMIZED ENLIVEN CLINICAL TRIAL ACCORDING TO SURGICAL HISTORY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST